Safety and immunogenicity of palivizumab (Synagis) administered for two seasons

Donald Null, Bernard Pollara, Penelope H. Dennehy, Jean Steichen, Pablo J. Sanchez, Laurence B. Givner, David Carlin, Bernard Landry, Franklin H. Top, Edward Connor

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

To evaluate the safety and inimunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab (Synagis) during the subsequent year. The single child with an antipalivizumab titer of >1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.

Original languageEnglish (US)
Pages (from-to)1021-1023
Number of pages3
JournalPediatric Infectious Disease Journal
Volume24
Issue number11
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

    Fingerprint

Keywords

  • Monoclonal antibody
  • Palivizumab
  • Respiratory syncytial virus
  • Synagis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Null, D., Pollara, B., Dennehy, P. H., Steichen, J., Sanchez, P. J., Givner, L. B., Carlin, D., Landry, B., Top, F. H., & Connor, E. (2005). Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatric Infectious Disease Journal, 24(11), 1021-1023. https://doi.org/10.1097/01.inf.0000183938.33484.bd